Stocktoria
China SXT Pharmaceuticals, Inc. SXTC
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-01-04
China SXT Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.7M | $1.9M | $2.0M | $2.6M | $4.8M |
| Gross profit | $367,427 | $553,971 | $426,271 | $1.3M | $2.8M |
| R&D expense | — | $184,194 | $200,717 | $367,005 | — |
| Operating income | -$2.7M | -$2.5M | -$5.6M | -$5.2M | -$2.2M |
| Interest expense | — | — | $476,776 | $36,695 | $1.6M |
| Income tax | — | — | — | $328,146 | -$192,683 |
| Net income | -$3.3M | -$3.1M | -$5.9M | -$5.7M | -$2.7M |
| EPS (diluted) | $-2.32 | $-28.58 | $-177.84 | $-137.92 | $-3.82 |
| Operating cash flow | -$2.3M | -$1.9M | -$80,757 | $268,293 | -$1.3M |
| Cash & equivalents | $18.1M | $12.1M | $17.4M | — | $13.4M |
| Inventory | $828,053 | $794,855 | $531,254 | $1.0M | $859,696 |
| Total assets | $21.7M | $23.1M | $29.6M | $33.5M | $34.5M |
| Total liabilities | $6.2M | $9.2M | $14.9M | $17.1M | $18.6M |
| Shareholders' equity | $15.4M | $13.9M | $14.7M | $16.1M | $16.0M |
Source: SEC EDGAR filings · CIK 0001723980 · as of 2025-03-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.